rs689466 — PTGS2 A-1195G

Promoter variant in the PTGS2/COX-2 gene that reduces baseline COX-2 expression, increasing susceptibility to ulcerative colitis and modifying colorectal cancer and cardiovascular risk

See your personal result for PTGS2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PTGS2 A-1195G — When COX-2's Off Switch Is Stuck On

COX-211 COX-2
Cyclooxygenase-2, encoded by PTGS2, is the inducible isoform of prostaglandin synthase that produces prostaglandins in response to inflammation, injury, and immune signals — distinct from the constitutive COX-1 isoform, which protects the gastric lining is the enzyme that makes prostaglandins — the molecular messengers that drive fever, pain, and the redness and swelling of inflammation. It is also the primary target of NSAIDs including aspirin, ibuprofen, and the now-restricted COX-2 selective inhibitors (coxibs). The rs689466 variant, located 1,195 bases upstream of the PTGS2 transcription start site, sits in the promoter region that controls how much COX-2 protein your cells make. The G allele (reported as C on the genomic plus strand) is associated with reduced COX-2 inducibility — a counterintuitive situation where lower inflammation capacity creates, not prevents, inflammatory disease risk.

The Mechanism

The PTGS2 promoter contains several regulatory elements including NF-kB binding sites, CRE (cAMP response element), and E-box sequences. The A-1195G substitution22 A-1195G substitution
This notation uses coding-strand orientation; PTGS2 is on the minus strand, so the genomic plus-strand alleles are T (reference) and C (variant). All genotype labels below use plus-strand notation as reported by genome files falls within a region that influences transcriptional responsiveness. The G/C variant allele appears to reduce the promoter's ability to drive robust COX-2 expression in response to inflammatory stimuli. This creates a paradox: reduced COX-2 means impaired prostaglandin production in the gut mucosa, where prostaglandins normally support epithelial barrier integrity, mucosal repair, and immune tolerance to luminal antigens. A gut that cannot mount an adequate COX-2 response is paradoxically more susceptible to chronic inflammatory disease — the same mechanism thought to explain why long-term NSAID use (which suppresses COX-2) increases IBD flares and colonic permeability in some patients.

The Evidence

The strongest human evidence comes from a Scottish-Danish case-control study by Andersen et al.33 Andersen et al.
Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study. Inflamm Bowel Dis, 2011 involving 732 Crohn's disease cases, 973 ulcerative colitis cases, and 1,157 healthy controls. Carriers of the A-1195G variant allele had significantly increased UC risk (OR 1.25, 95% CI 1.02–1.54, P=0.03). The effect was amplified in never-smokers (OR 1.47 for IBD, OR 1.37 overall), and the variant was associated with earlier UC onset (before age 40) and more extensive colitis presentation. No significant association with Crohn's disease was found, suggesting the mechanism is UC-specific — consistent with COX-2's role in colonic epithelial barrier maintenance.

For colorectal cancer, the picture is more complex and requires careful interpretation. A meta-analysis of 16 studies44 meta-analysis of 16 studies
Zhang et al. World J Surg Oncol, 2020; 8,998 cases and 11,917 controls found no overall association between rs689466 and CRC risk in the full multi-ethnic population, but a positive association emerged in Caucasians specifically. Critically, the risk is highly dependent on gene-environment interactions: Pereira et al.55 Pereira et al.
Genetic variability in key genes in prostaglandin E2 pathway and colorectal cancer. PLoS One, 2014 found that CC homozygotes who were ever-smokers had approximately 6-fold increased CRC susceptibility (OR ~6, 95% CI 1.49–22.42, P=0.011), while non-smokers showed no significant risk elevation. An independent study Andersen et al.66 Andersen et al.
Interactions between diet, lifestyle and gene polymorphisms in colorectal cancer. PLoS One, 2013 confirmed interactions with meat intake, fiber, and smoking. A third paper found variant allele carriers had OR 3.23 (95% CI 1.52–6.86)77 OR 3.23 (95% CI 1.52–6.86)
Pereira et al. Clin Transl Gastroenterol, 2016 for colorectal adenoma development — the precursor lesion to most CRCs.

One contradictory study Vogel et al.88 Vogel et al.
Intestinal PTGS2 mRNA levels and colorectal carcinogenesis. PLoS One, 2014 reported reduced CRC risk in variant allele carriers (OR 0.52, 95% CI 0.28–0.99), highlighting that the direction of effect may differ by tissue context, disease stage, and patient selection. Overall evidence for colorectal cancer risk is moderate and context-dependent.

Practical Implications

For CT and CC genotype carriers, the most actionable implication is colorectal screening and smoking avoidance. The gene-smoking interaction for colorectal cancer is the strongest documented risk amplifier: smoking while carrying the CC genotype generates disproportionate CRC susceptibility beyond the additive risks. Standard colorectal screening protocols (colonoscopy from age 45) remain the primary risk reduction tool. For those with a personal or family history of IBD, awareness that this variant is associated with ulcerative colitis risk and more extensive disease presentation is clinically relevant. COX-2 inhibiting NSAIDs (ibuprofen, aspirin, naproxen, celecoxib) blunt an already-reduced COX-2 pathway — carriers with IBD should discuss NSAID use with a gastroenterologist, as long-term NSAID use may worsen mucosal barrier function in those with low baseline COX-2 activity.

Interactions

The PTGS2 promoter region harbors a second functional polymorphism, rs20417 (COX-2 -765G>C), which has also been associated with IBD and colorectal cancer risk. These two promoter variants are in partial linkage disequilibrium in some populations and may act cooperatively to reduce PTGS2 promoter activity — a compound effect worth investigating in multi-variant models. Another PTGS2 3'UTR variant, rs5275 (T8473C), has been studied in relation to CRC with NSAID interaction; carriers of both rs689466 and rs5275 variant alleles may have altered total COX-2 regulation affecting NSAID response.

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal COX-2 Promoter Normal

Normal COX-2 promoter activity — standard IBD and colorectal cancer risk

You carry two copies of the reference T allele at this PTGS2 promoter position (equivalent to AA in coding-strand notation used in most papers). This is the most common genotype globally — approximately 67% of people of European descent share it. Your PTGS2 promoter drives normal COX-2 inducibility in response to inflammatory stimuli, supporting standard mucosal repair capacity and prostaglandin-mediated immune homeostasis. No elevated risk for ulcerative colitis or colorectal cancer from this variant.

CT Reduced COX-2 Inducibility Intermediate

One copy of the variant allele — modestly reduced COX-2 promoter activity and elevated UC susceptibility

The A-1195G variant reduces the inducibility of the PTGS2 promoter — meaning your gut mucosal cells may produce less COX-2 protein in response to inflammatory challenges. This matters because COX-2-derived prostaglandins in the colon support epithelial barrier integrity, promote mucosal healing after injury, and help maintain immune tolerance to the gut microbiome. Reduced COX-2 inducibility leaves the colonic mucosa with impaired healing capacity, paradoxically increasing susceptibility to the chronic inflammation that defines ulcerative colitis. The effect was most pronounced in never-smokers, suggesting tobacco compensates through some independent pro-inflammatory pathway — though smoking increases colorectal cancer risk through separate mechanisms.

CC Low COX-2 Inducibility High Risk

Homozygous variant — substantially reduced COX-2 promoter activity, highest IBD and colorectal cancer susceptibility among rs689466 genotypes

The CC genotype is associated with the lowest PTGS2 promoter inducibility, resulting in substantially reduced COX-2 protein production in response to inflammatory triggers. In the colon, where COX-2-derived prostaglandins maintain mucosal barrier integrity and coordinate immune tolerance of luminal bacteria, this creates chronic susceptibility to barrier dysfunction — the foundation of ulcerative colitis pathogenesis. The association with earlier UC onset (before age 40) and more extensive disease suggests that CC carriers who develop UC tend toward the more severe end of the disease spectrum.

For colorectal carcinogenesis, the mechanism involves prostaglandin E2 (PGE2), which normally exerts complex dose-dependent effects on colonic epithelial cell proliferation and immune surveillance. Paradoxically, insufficient COX-2 activity may impair anti-tumor immune surveillance in some contexts, while excess COX-2 activity promotes tumor vasculature in others — explaining why both very low and very high COX-2 expression are associated with cancer risk in different study contexts.

The dramatic smoking interaction (OR ~6 for CC homozygotes who ever smoked) reflects tobacco carcinogen metabolism intersecting with an already-impaired mucosal defense system. For CC carriers who smoke or have smoked, earlier and more intensive colorectal screening is strongly advisable.